Last week, researchers found that exercise can counteract the cognitive decline some patients experience post-breast cancer treatment. It’s the 457th publication since 2012 to use a Fitbit device in research. Or to put it a different way, this study found that 83 percent of clinical trials used a Fitbit as opposed to another brand. Researchers apparently just really prefer it. That’s good news for the company, since it now has a slew of clinical data under its belt, and it’s thinking about a run at a medical device designation a few years in the future. According to their GM of Health Solutions, “as we start going deeper down the health road with more and more advanced sensors, I’d say, just stay tuned.” Oooooh, mysterious.
Last week, medical device manufacturing company, Medtronic, and wearable tech company, Fitbit, announced plans to merge health and activity tracking for people with diabetes. By tracking activity levels and glucose levels together, patients and their doctors can get a better view of how exercise impacts their glucose levels. People with Type 2 diabetes won’t have to carry around sheets of paper, manually log their blood sugar levels, remember (or misremember) exercise details and outcomes. Anything that reduces pain—physical or mental—will be welcomed by those with diabetes. In our humble opinion, the migration from consumer activity monitoring to real healthcare is an enormous leap for consumer wearables.